Investment opportunities
Open for Investment
Lipozyt Marker
Diagnostic Tests for the Personalized Treatment of Type 2 Diabetes
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreeOpen for Investment
PharmGenomics
Coronascreen: Contactless, online-based Laboratory Diagnostics
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreeOpen for Investment
ImmunoLogik
Patent pending therapy solution for the treatment of SARS-CoV-2 and diseases caused by future corona viruses
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreeOpen for Investment
Proteona Antibody Protection
Development of an antibody therapy to protect against COVID-19 using proteogenomic single cell sequencing
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreePrivate Placement
Emperra
Helping to make life with Diabetes mellitus easier
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreePrivate Placement
Alma Bio Therapeutics
Employs the Language of the Immune System to Improve Patients’ Health
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreePrivate Placement
Mowoot
Solving intestinal transit disorders purely physical, non-drug, non-invasive.
This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de
Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.
I agreePrivate Placement
NanoVelos
Getting drugs to their targets with significant side effects reduction
New from the blog
-
Read full story
10.07.2020
Investors in the Time of the Pandemic Meet Virtually at the Sachsforum
This week, the digital Novel Coronavirus Investment Forum (NCIF) offered a forward-looking analysis of the revolution in healthcare
-
Read full story
10.07.2020
Proteona and Aescuvest Cover 546 Kilometres in the Run Against Cancer
Since 2012, the National Center for Tumor Diseases (NCT) Heidelberg has been organizing a charity run against cancer. This year, Proteona teamed up with Aescuvest for the good cause.
-
Read full story
04.06.2020
How Surge-On Medical Defines the Future of Surgery
Defining the future of robotic surgery training and MIS instruments: Surge-on Medical started shaping their own VR trainer to deliver more value to the users.
-
Read full story
29.05.2020
Overview of Surge-on Medical’s campaign
The last nine months have been a thrill for Surge-on Medical. Since the launch of our equity crowdfunding campaign in August 2019, the company has been focused on raising funds and getting in touch with investors across Europe, without losing sight of daily operations and preparations for the future.
-
Read full story
20.05.2020
EIT Health Start-Up Rescue Instrument
Start-ups can now apply to receive up to €500,000 in co-investment from EIT Health in return for options. Through the new Start-up Rescue Instrument, EIT Health aims to alleviate the economic shock posed by the COVID-19 pandemic.
-
Read full story
13.05.2020
#CrowdBeatsCorona
Aescuvest Leads Alliance of Crowdfunding Platforms in Fight Against COVID-19
-
Read full story
13.05.2020
Steerable Punch Now with CE Mark
Surge-on Medical has achieved a great milestone this week: The Steerable Punch for knee arthroscopy has been registered and is recognized with the CE mark for Class I medical devices
-
Read full story
23.04.2020
Moving Forward Despite the Global Challenges
It was a successful 2019 for Surge-on Medical, as we overcame the equity crowdfunding barrier at Aescuvest.eu, a great way to end the preceding year.
-
Read full story
09.04.2020
In COVID-19-Times, Crowdfunding Could Serve as a Lifeline
Start-up CEOs will tell you that, even at the best of times, funds are difficult to raise. The slowdown (ok, crash landing) of economic activity the COVID-19 pandemic has caused, has all but dried up access to finance through conventional channels (e.g. venture capital).
-
Read full story
22.03.2020
#TakeBackControl
The coronavirus is spreading rapidly all over the world. Now is the time to get a grip on the global threat. In order to flatten the curve, fast reaction is essential.